pharmaceutical intelligence, offering a company with a genuine thirst for scientific advancement, but with the practical know-how to be able to bring products to the market and enhance the lives of patients. With a notable expertise in cardiology, Cardiorentis AG is initially concentrating its efforts on ularitide for the treatment of acute cardiovascular indications, with the aim of developing the first evidence-based drug treatment for acute heart failure (AHF).Cardiorentis is proud of the strong partnerships it has built with academic researchers, universities and practicing clinicians across the world; all working closely together to drive important research forward. United by their common goal, they believe that their actions today will shape the future of patient care tomorrow.